Metagenomi

MGX

Market cap $117M

Metagenomi (MGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.29 per share a year ago.

Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $ 205.0 million in cash, cash equivalents and available-for-sale marketable securities as of June 30, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today reported financial results for the quarter ended June 30, 2025, and provided business updates.

EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors.

- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders -

Metagenomi (MGX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.19 per share a year ago.

- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety profile

EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: an oral presentation at TIDES USA 2025, taking place May 19-22, 2025, at the Manchester Grand Hyatt San Diego, and three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, LA and virtually.

Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months

Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells Expression of the compact CAST system from a single 'all-in-one' mRNA design represents a first-in-class approach to simplifying delivery for therapeutic applications Additional updates on further advancements in novel large gene integration technology anticipated in 2025 EMERYVILLE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced a publication in the journal Nature Communications  describing its novel, compact CAST system for large, targeted gene integration into the human genome.

EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will host one-on-one investor meetings at the conference.